These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27531419)

  • 21. Investigation of the capacity of low glass transition temperature excipients to minimize amorphization of sulfadimidine on comilling.
    Curtin V; Amharar Y; Hu Y; Erxleben A; McArdle P; Caron V; Tajber L; Corrigan OI; Healy AM
    Mol Pharm; 2013 Jan; 10(1):386-96. PubMed ID: 23186332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of a Salt Coformer in a Co-Amorphous Drug System Dramatically Enhances the Glass Transition Temperature: A Case Study of the Ternary System Carbamazepine, Citric Acid, and l-Arginine.
    Ueda H; Wu W; Löbmann K; Grohganz H; Müllertz A; Rades T
    Mol Pharm; 2018 May; 15(5):2036-2044. PubMed ID: 29630842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. (Co-)amorphization of enantiomers - Investigation of the amorphization process, the physical stability and the dissolution behavior.
    Holzapfel K; Liu J; Rades T; Leopold CS
    Int J Pharm; 2022 Mar; 616():121552. PubMed ID: 35131351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems.
    Wu W; Löbmann K; Rades T; Grohganz H
    Int J Pharm; 2018 Jan; 535(1-2):86-94. PubMed ID: 29102703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of Solvent Composition on the Performance of Spray-Dried Co-Amorphous Formulations.
    Mishra J; Rades T; Löbmann K; Grohganz H
    Pharmaceutics; 2018 Apr; 10(2):. PubMed ID: 29649124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-amorphous systems consisting of indomethacin and the chiral co-former tryptophan: Solid-state properties and molecular mobilities.
    Holzapfel K; Rades T; Leopold CS
    Int J Pharm; 2023 Apr; 636():122840. PubMed ID: 36921746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co amorphous systems: A product development perspective.
    Chavan RB; Thipparaboina R; Kumar D; Shastri NR
    Int J Pharm; 2016 Dec; 515(1-2):403-415. PubMed ID: 27771485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of variation in molar ratio on co-amorphous drug-amino acid systems.
    Jensen KT; Larsen FH; Löbmann K; Rades T; Grohganz H
    Eur J Pharm Biopharm; 2016 Oct; 107():32-9. PubMed ID: 27368747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mitigating unwanted amorphisation: A screening method for the selection of suitable excipients.
    Amharar Y; Curtin V; Gallagher KH; O'Siochru E; O'Connell P; Healy AM
    Eur J Pharm Sci; 2016 Jan; 81():181-8. PubMed ID: 26493586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amorphization of itraconazole by inorganic pharmaceutical excipients: comparison of excipients and processing methods.
    Grobelny P; Kazakevich I; Zhang D; Bogner R
    Pharm Dev Technol; 2015 Jan; 20(1):118-27. PubMed ID: 25312240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poly (amino acid)s as new co-formers in amorphous solid dispersion.
    Huang Q; Zou Z; Li X; Xiao Q; Liang G; Wu W
    Int J Pharm; 2023 Mar; 634():122645. PubMed ID: 36706970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-Amorphous Combination of Nateglinide-Metformin Hydrochloride for Dissolution Enhancement.
    Wairkar S; Gaud R
    AAPS PharmSciTech; 2016 Jun; 17(3):673-81. PubMed ID: 26314243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
    Caron V; Tajber L; Corrigan OI; Healy AM
    Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules.
    Sou T; Kaminskas LM; Nguyen TH; Carlberg R; McIntosh MP; Morton DA
    Eur J Pharm Biopharm; 2013 Feb; 83(2):234-43. PubMed ID: 23183447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of the cooling rate and the blend ratio on the physical stability of co-amorphous naproxen/indomethacin.
    Beyer A; Grohganz H; Löbmann K; Rades T; Leopold CS
    Eur J Pharm Biopharm; 2016 Dec; 109():140-148. PubMed ID: 27746228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of physical properties and stability of indomethacin-cimetidine and naproxen-cimetidine co-amorphous systems prepared by quench cooling, coprecipitation and ball milling.
    Lim AW; Löbmann K; Grohganz H; Rades T; Chieng N
    J Pharm Pharmacol; 2016 Jan; 68(1):36-45. PubMed ID: 26663364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Formation of physically stable amorphous drugs by milling with Neusilin.
    Gupta MK; Vanwert A; Bogner RH
    J Pharm Sci; 2003 Mar; 92(3):536-51. PubMed ID: 12587115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The influence of co-formers on the dissolution rates of co-amorphous sulfamerazine/excipient systems.
    Gniado K; Löbmann K; Rades T; Erxleben A
    Int J Pharm; 2016 May; 504(1-2):20-6. PubMed ID: 26992818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An example of how to handle amorphous fractions in API during early pharmaceutical development: SAR114137--a successful approach.
    Petzoldt C; Bley O; Byard SJ; Andert D; Baumgartner B; Nagel N; Tappertzhofen C; Feth MP
    Eur J Pharm Biopharm; 2014 Apr; 86(3):337-50. PubMed ID: 24075979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism for Stabilizing an Amorphous Drug Using Amino Acids within Co-Amorphous Blends.
    Guinet Y; Paccou L; Hédoux A
    Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.